AcelRx stock takes hard hit after unexpected FDA request
The specialty pharmaceutical company suffered an almost 40 percent drop in stock price, after an unanticipated FDA request was made right before the company announced its fourth quarter earnings.
AcelRx stock takes hard hit after unexpected FDA request Read More »